The mechanism underlying p210 BCR/ABL oncoprotein-mediated transformation in chronic myelogenous leukemia (CML) is not fully understood. We hypothesized that p210 BCR/ABL suppresses expression of genes which may explain at least some of the pathogenetic features of CML. A subtractive cDNA library was created between BCR/ABL-enhanced-green-fluorescentprotein (GFP)-transduced umbilical cord blood (UCB) CD34 
Introduction
Chronic myelogenous leukemia (CML) is a malignancy of the hematopoietic stem cell 1 caused by the Philadelphia chromosome 2 and the resulting p210 BCR/ABL cytoplasmic oncoprotein. 3 Clinically, CML is characterized by increased proliferation, 4, 5 increased resistance to apoptosis [6] [7] [8] and altered adhesion and migration. [9] [10] [11] [12] The increased Abl tyrosine kinase activity caused by its association with BCR, leads to phosphorylation of Crk-L, RAS-GAP, Paxillin, Fak, phosphoinositide 3-kinase (PI3K), as well as p210 BCR/ABL itself, which creates binding sites for a number of adaptor proteins. As a result, p210 BCR/ABL activates mitogenic and antiapoptotic signals through RAS, mitogenactivated protein (MAP) kinase, Janus kinase-signal transducers and activators of transcription (Jak-Stat), PI3K and myc. BCR/ ABL also induces multiple abnormalities of cytoskeletal function, 13, 14 which in cell lines leads to increased adhesion to fibronectin, 15 but in primary human CML progenitor cells decreases adhesion to bone marrow stroma and extracellular matrix. 9, 10 A causal role for the abnormal adhesion and migration has been shown for b1-integrins. 10, 16, 17 The role of other adhesion molecules, such as, selectins, sialomucins and chemokines in the aberrant adhesion and migration properties observed in CML has been less clarified.
Aside from affecting protein function, there is also evidence that presence of p210 BCR/ABL may affect more global gene expression patterns. Deregulated gene expression has been studied in BCR/ABL-transformed cell lines, [18] [19] [20] [21] and we have recently reported on the increased expression of a number of genes in primary CD34
þ cells as a result of p210 BCR/ABL . 22, 23 We here hypothesized that presence of p210 BCR/ABL may also downregulate expression of known and yet to be identified genes that may contribute to BCR/ABL-mediated malignant transformation in CML.
Materials and methods

Cell lines and materials
K562 cells were obtained from American Type Culture Collection (ATCC) (CCL-243) and maintained in Iscove's modified Dulbecco's medium (IMDM; Invitrogen, Carlsbad, CA, USA) supplemented with 10% FCS (HyClone, Logan, UT, USA) and 1% L-glutamine (Invitrogen). The 293 cell line was obtained from ATCC (CCL-86) and maintained in Dulbecco's minimal essential medium (DMEM) with high glucose (Invitrogen) with 10% FCS. Antibodies used in this study were directed against, b-actin (monoclonal IgG1; Santa Cruz Biotech., Santa Cruz, CA, USA), ABL (monoclonal IgG1; Santa Cruz Biotech.), phosphotyrosine (mouse monoclonal IgG1; UBI, Lake Placid, NY). Imatinib was a generous gift from Novartis (Basel, Switzerland).
Primary CD34
þ cells
Bone marrow (BM) was obtained from nine patients with early CP BCR/ABL-positive CML and nine NL healthy volunteers. In addition, we obtained 35 UCB samples from healthy term deliveries. All samples were obtained after informed consent using guidelines approved by the Committee on the Use of Human Subjects at the University of Minnesota. CD34 þ cellenriched populations were selected from mononuclear cells using immunomagnetic columns (Miltenyi Biotec, Sunnyvale, CA, USA). Purity of CD34 þ cells after two passes over the immunomagnetic columns was 490%.
Transduction of UCB CD34
þ cells UCB CD34 þ cells were transduced with an MSCV-based retroviral vector containing either GFP cDNA alone (M-GFP) or the BCR/ABL cDNA upstream from an IRES-GFP sequence (M-p210-GFP) as described. 24 
Primary CD34
þ cell culture
After fluorescence-activated cell sorting (FACS) and before lysis for RNA or protein extraction, CD34 þ cells were maintained for 12-16 h in serum-free medium with low-dose cytokines consisting of BIT-9500 (Stem Cell Technologies, Vancouver, British Columbia, Canada) supplemented with IMDM, 50 mM 2-mercaptoethanol (Sigma; St. Louis, MO, USA), 40 mg/ml lowdensity lipoprotein (Sigma), 250 pg/ml granulocyte colony stimulating factor (G-CSF; Amgen; Thousand Oaks, CA, USA), 10 pg/ml granulocyte-macrophage colony stimulating factor (GM-CSF; Immunex; Seattle, WA, USA), 1 ng/ml interleukin-6 (IL-6; R&D Systems; Minneapolis, MN, USA), 50 pg/ml leukemia inhibitory factor (LIF; R&D Systems), 200 pg/ml macrophage inflammatory factor (MIP-1a; R&D Systems), and 200 pg/ml stem cell factor (SCF; Amgen). For imatinib mesylate (Imatinib) studies, CD34 þ cells were maintained for 48 h in serum-free medium with low-dose cytokines in the presence of 1 mM Imatinib.
Subtractive library
A cDNA library created as described 22 was used to identify downregulated genes. Differential screening was performed by high-throughput dot blot analysis using the PCRSelect differential screening kit according to the manufacturer's protocol (Clontech) and as reported. 22 Sequencing cDNA clones that were confirmed downregulated in BCR/ ABL þ GFP þ cells in the high throughput dot blot screen were sequenced using the dye Terminator Cycle Sequencing kit (Applied Biosystems, Foster City, CA, USA). Sequences were characterized by BLAT (human genome working draft), BLAST algorithm to SwissProt, GenBank protein and nucleotide collections, murine and human EST contigs. The sequences were considered part of known genes if they shared 495% homology over at least a 100-bp DNA sequence by BLAST search.
Q-RT-PCR
Total RNA from GFP or p210 UCB CD34 þ cells, or from NL or CML BM CD34 þ cells was isolated using the RNeasy procedure (Qiagen) and used for Quantitative RT-PCR using the SYBR green method, as described. 22 Primers used are listed in Table 1 .
Western blotting
A total of 5 Â 10 4 GFP or p210 UCB CD34 þ cells, and CML or NL BM CD34 þ cells were used to assess the presence of p210 BCR/ABL , and to assess global phosphorylation patterns, using methods as previously described. 22 
Flow cytometry
Expression of L-selectin (PE-conjugated anti-CD62L, eBioscience), ICAM-1 (PE-conjugated anti-CD54, eBioscience) CD34 (APC-conjugated anti-CD34, BD Biosciences) was analyzed by FACS-Calibur (Becton-Dickinson) using the CellQuest Pro software. To study CCR7 expression, cells were labeled sequentially with an anti-CCR7 mouse monoclonal antibody (R&D Systems) and rat-anti-mouse-PE (BD-Biosystems).
Chemotaxis assay
Chemokine-dependent chemotaxis of GFP or p210 CD34 þ UCB cells, and NL or CML BM CD34 þ cells was determined using Costar Transwells (6.5-mm, 5-mm pore size, polycarbonate membrane). 25 The transwell inserts were coated with 100 mg/ml fibronectin (FN) or bovine serum albumin (BSA) (both from Sigma) for 12 h at 41C. The solution was then removed and inserts were blocked with 2% BSA for 30 0 at room temperature and washed with IMDM. Prior to use in chemotaxis assay, cells were preincubated for 12 h in X-VIVO 15 (Bio Whittaker) media supplemented with 2.5 ng/ml G-SCF, 100 pg/ml GM-CSF, 10 ng/ ml IL-6, 2 ng/ml MIP1a, 2 ng/ml SCF and 500 pg/ml LIF. After washing, 2-4 Â 10 5 GFP or p210 UCB CD34 þ cells, or NL BM or CML CD34 þ cells were resuspended in 100 ml of X-VIVO15 without cytokines and placed in duplicate in the transwell inserts. The same media with or without 1 mg/ml chemokine ligand 19 (CCL19) (R&D Systems) or 2 mg/ml CCL21 (R&D Systems) was added in the bottom chamber. In selected Downregulated genes implicated in adhesion and motility in CML M Jongen-Lavrencic et al experiments, cells were preincubated for 15 0 at 371C and 5% CO 2 with anti-human-CCR7 blocking antibody (R&D Systems) or IgG-isotype control (R&D Systems) prior to plating in the transwell inserts. In all samples, 2 Â 10 5 polystyrene microbeads (Polyscience, Inc.) were added to the cell solution to allow enumeration of migrated cells. Cell migration was allowed for 4-4.5 h at 371C and 5% CO 2 . Cells that migrated through the transwell were harvested from the bottom chamber and the number of migrated CD34 þ cells determined by FACS-Calibur (Becton-Dickinson). Cells were labeled with a PE-conjugated anti-CD34 þ antibody (BD Biosciences) and gated on eGFP þ CD34 þ (transduced UCB samples) or CD34 þ (primary BM samples) cells. The percent migration was calculated using polystyrene beads (Polyscience, Inc.) as an internal control.
Statistics
The significance of differences between mRNA levels and migration percentage GFP and p210 UCB CD34 þ samples was determined using a paired Student's t-test. The significance of the difference between mRNA levels and migration percentage between NL and CML BM CD34 þ cells was analyzed by Student's t-test with unequal variance.
Results
Genes downregulated in p210 UCB and in ECP CML CD34 þ cells
We used the cDNA library previously generated 22 to identify genes that are downregulated as a result of introduction of the BCR/ABL cDNA in UCB CD34 þ cells. Of the 1000 clones identified by subtractive hybridization, 13% were confirmed lower expressed in p210 than GFP UCB CD34 þ cells after performing a high-throughput dot blot analysis. These cDNA clones were sequenced and characterized by comparison to available on-line databases. To confirm differential expression, we generated additional GFP and p210 UCB CD34 þ samples. Expression of BCR/ABL mRNA transcripts in p210 UCB CD34 Q-RT-PCR, using sequence specific primers listed in Table 1 , demonstrated that eight genes identified in the subtractive screen were downregulated in an additional 5-6 samples of Mean fold change (standard error) between imatinibÀ and imatinib+.
Downregulated genes implicated in adhesion and motility in CML M Jongen-Lavrencic et al independently BCR/ABL-transduced UCB CD34 þ as well as early CP CML BM-derived CD34 þ cells (Table 2) . These included ICAM1, L-selectin, CCR7, Sortilin (SORL1), hematopoietic cell kinase (HCK) baculoviral IAP repeat-containing protein 1 (BIRC1), myxovirus resistance 1 (MX1) and NF1.
Imatinib treatment restores normal levels of mRNA of some but not all genes
We next evaluated whether downregulation of these genes could be specifically attributed to the increased Abl tyrosine kinase activity in CML cells. We treated GFP and p210 UCB CD34 þ cells, or CML and NL BM CD34 þ cells with 1 mM Imatinib for 48 h. This resulted in decreased overall protein phosphorylation (Figure 1b) . In p210 UCB CD34 þ cells (Table 3) , Imatinib reversed transcript levels of 7/8 of the downregulated genes to approximately normal levels (ICAM1, L-selectin, CCR7, SORL1, HCK, BIRC1 and NF1), but did not affect mRNA levels of MX1. For CML CD34 þ cells, Imatinib significantly increased levels of mRNA for all genes except for MX1 (Table 3) .
Decreased protein expression of L-selectin and ICAM1 on p210 containing CD34 þ cells
We next tested whether results seen at the mRNA level held true at the protein level. For these studies, we focused on gene products involved with cell adhesion and migration. In accordance with mRNA results, we found that a lower number of p210 UCB and CML BM CD34 þ cells expressed L-selectin and ICAM1 (Figure 2a ) compared with GFP UCB or NL BM CD34 þ cells. Upon treatment of p210 UCB CD34 þ cells with imatinib the fraction of cells expressing L-selectin or ICAM1 was unchanged, while for early CP CML CD34 þ cells, expression of L-selectin but not ICAM1 increased (Figure 2b ). We were unable to detect CCR7 protein expression on CD34 þ cells, even though the antibody did stain normal T-lymphocytes (data not shown).
CCR7 ligands fail to induce migration of p210 UCB and early CP CML CD34 þ cells
We used the CCR7 ligands, CCL19 and CCL21, in two-chamber migration assay to assess the function of CCR7 in p210 containing cells. Migration of UCB CD34 þ cells towards CCL19 was blocked by 100 mg/ml CCR7 blocking antibody (not shown), supporting the notion that migration driven by this ligand was specific for the CCR7 receptor.
We observed lower spontaneous migration of p210 UCB and early CP CML CD34 þ cells over fibronectin-coated membranes as compared to GFP þ UCB and NL BM CD34 þ cells (Figure 3 ). Both, CCL19 and CCL21 increased migration of GFP-CD34 þ UCB cells (Figure 3a) and NL BM CD34 þ cells (Figure 3b ). However, these ligands did not enhance migration of p210 UCB (Figure 3a) or CML BM CD34 þ cells (Figure 3b ). Treatment of p210 UCB cells and CML CD34 þ cells with STI571 did not restore migration to CCL19 or CCL21 (Figure 3c-f) .
Discussion
We have previously demonstrated that the model of CML used here, BCR/ABL-transduced UCB CD34 þ cells, recreates all important features of early CP CML, namely altered adhesion, increased proliferation and inhibited apoptosis, 24 and is suitable to study molecular mechanisms through which BCR/ABL causes functional defects in CML CD34 þ cells. One benefit compared to using CD34 þ cells from primary early CP CML patients is that transduction of BCR/ABL into UCB CD34 þ cells allows study of the effect of BCR/ABL on cell behavior without possible interference from other genetic abnormalities due to the longstanding presence of BCR/ABL, even in early CP CML. We show Using a similar strategy, we here identified multiple genes that are downregulated upon introduction of BCR/ABL in primary CD34 þ cells derived from UCB. Furthermore, we confirmed decreased expression of these genes in CD34
þ cells of patients with early CP CML as compared to NL BM CD34 þ cells. Three of the eight downregulated genes, L-selectin, ICAM1 and CCR7, are implicated in cell adhesion and motility but their role in CML is not yet known. There is a significant body of evidence that abnormal expression and/or function of cell adhesion molecules contributes to the pathophysiology of CML. 26, 27 For instance, we and others have shown abnormal b1-integrin function in CML, 9,10,17,28 which could be reversed by interferon-a 28 or BCR/ABL-tyrosine kinase inhibitors, 11 two drugs used to treat CML.
We demonstrate here that mRNA and protein levels of ICAM1 are decreased in CD34 þ cells expressing the p210 BCR/ABL oncoprotein, and that mRNA levels of this adhesion molecule are only moderately increased following treatment with Imatinib. The role of ICAM1 in hematopoiesis has not been extensively studied. ICAM1-homozygous deficient animals have moderate granulocytosis, 29 possibly consistent with the pronounced granulocytosis seen in CML. Baron et al 30 recently reported that presence of BCR/ABL in UT-7 cell is associated 
Po0.05 compared to the control (medium without ligand). (c-f) GFP (c) and p210 (d) UCB cells and NL (e) and CP CML (f) CD34
þ cells were treated with (white bars) or without (black bars) 1 mM imatinib and plated in the upper chamber of transwell transmigration assays. The percent migrated CD34 þ cells to CCR7 ligands (CCL19 and CCL21) was calculated as described in Materials and methods.
Downregulated genes implicated in adhesion and motility in CML M Jongen-Lavrencic et al with increased ICAM1 expression, which appears at odds with our results. However, differences in target cell (cell line vs primary human CD34 þ cells) may play a role in the discrepancy with our results, similar to differences reported for the role of b1-integrins in normal compared with CML hematopoiesis when studied in cell line models 15 and primary CML cells.
11
Selectins (L-, P-, and E-selectin) are a family of glycoproteins that mediate adhesive interactions with their ligands under shear. L-selectin is expressed on early hematopoietic progenitors and there is evidence from cell migration experiments, clonogenic assays, and clinical studies that L-selectin may play a role in the trafficking of hematopoietic progenitors and hematopoiesis. [31] [32] [33] [34] [35] [36] [37] Decreased mRNA levels for L-selectin in p210 UCB and early CP CML CD34 þ cells is consistent with published reports demonstrating decreased expression of L-selectin on BM CD34 þ cells derived from CML patients. [38] [39] [40] We observed populations of CD34 þ cells with higher and lower levels of L-selectin protein expression in primary cells as well as in the UCB transduction model possibly based on subpopulations. Hence, it is possible that the decreased levels of ICAM1 and L-selectin in CML samples is due to skewing of the population away from the population expressing higher numbers of these adhesion molecules. However, as this was also seen in the transduced UCB model, we believe that skewing is less likely, as cells were evaluated within 48 h following transduction.
Fruehauf et al 40 also showed that imatinib restores expression of L-selectin in BCR-ABL-positive cell lines, a phenomenon we could not confirm in CD34 þ cells. Whether lack of L-selectin and/or ICAM1 play a role in the premature release of CD34 þ cells from the marrow in patients with CML will still need to be elucidated.
Chemokines are small chemotactic proteins that mediate their effect by binding to seven-transmembrane-spanning G protein coupled receptors. 41 They are implicated in migration of leukocytes, inflammatory responses and regulation of tumor growth, as well as hematopoiesis. [42] [43] [44] SDF1a and its receptor CXCR4 play important roles in migration of HSC from the fetal liver to the fetal BM 45, 46 as well as in postnatal life. 47, 48 In CML, chemotaxis towards SDF1a is impaired, 49, 50 which may contribute to the premature release of leukemic progenitors from the BM into the circulation. An other chemokine MIP1a, also affects the adhesive behavior of CML CD34 þ cells, even though a specific role for MIP1a in the retention of CD34 þ in the BM and/or homing to the BM has not been shown.
We here demonstrate that mRNA levels of CCR7, an other member of chemokine-receptor family, is downregulated in p210 UCB CD34 þ and CML BM CD34 þ cells, and hypothesize that CCR7 may a role in altered migration of p210 UCB CD34 þ cells. CCR7 is an important organizer of the primary immune response, regulating trafficking of T and B lymphocytes as well as DC to or within lymphoid organs.
51 CCL19 (ELC) and CCL21 (MIP-3beta) are ligands for CCR7 expressed within lymph nodes, Peyer's patches, spleen, endothelial cells of HEVs. [51] [52] [53] [54] Kim et al 55 showed that both CCR7 ligands, CCL19 and CCL21 have chemotactic activity for NL CD34 þ cells and suppress their proliferation. Although we attempted to evaluate the expression of CCR7 at the protein level, we were unable to detect significant levels of this chemokine receptor on either NL or leukemic CD34
þ cells with commercially available antibodies. However, as blocking antibodies against CCR7 inhibit migration of NL BM CD34 þ cells to its ligands, CCR7 must be expressed on NL CD34
þ BM cells and GFP þ UCB CD34 þ cells. Using a two-chamber migration system, we found that although CCR19 and CCR21 significantly increased migration of NL UCB and BM CD34 þ cells, they had no effect on BCR/ABL-containing CD34 þ cells. Whether the decreased levels of CCR7 in CML can explain the abnormal trafficking of CML progenitors, and may contribute to the abnormal proliferative behavior seen in CML needs to be further determined.
Of note, treatment with imatinib restored levels of mRNA for all three adhesion related proteins, but did not result in restoration of ICAM1 or L-selectin protein levels, nor the function of CCR7. The reason for this is not clear at this time. One possibility is that duration and/or concentration of imatinib treatment was insufficient to affect protein levels. However, we show that exposure to 1 mM imatinib reversed the abnormal protein phosphorylation pattern seen in CML, and that the enhanced phosphorylation of Crk-L was reversed. 22 Another possibility might be that the half-life of these adhesion molecules may be longer than 24 h, and that prolonged exposure of CD34 þ cells to imatinib may reverse the decreased protein expression. Obviously, it is also possible that the intracellular machinery needed for migration to occur is not affected by imatinib.
A possible role in the pathogenesis of CML has been described for two additional genes found suppressed in BCR/ ABL þ CD34 þ cells. NF1, encodes the protein neurofibromin, which is a negative regulator of the RAS signaling pathway. 56 Mutations in NF1 lead to juvenile myelomonocytic leukemia (JMML). 57, 58 Low levels of NF1 in CML CD34 þ cells may therefore contribute to deregulation of the RAS pathway as observed in CML. The second gene thought to play a role in CML pathogenesis, is HCK, the expression of which is restricted to myeloid cells 59 and couples BCR/ABL to STAT5 activation in murine 32Dcl3 myeloid cells. 60 A possible role in leukemia or hematopoiesis has not been identified for the last three genes suppressed as a result of expression of BCR/ABL, namely SORL1, MX1, and BIRC1.The structure of the sorLa-1 protein encoded by SORL1 suggests that this is an endocytic receptor possibly implicated in uptake of lipoproteins and proteases. 61 Whether this protein is important in hematopoiesis has not been addressed. The protein encoded by the BIRC1 gene contains regions of homology to two baculovirus inhibitors of apoptosis, and suppresses apoptosis induced by various signals. 62, 63 As CML is characterized by increased resistance to apoptosis, this result may seem contradictory to the pathophysiology of CML. However, apoptosis regulation is mediated by a number of different effectors, and the balance between multiple pro-and antiapoptotic genes decides the fate of the cell, rather than expression of one single gene product. The MX proteins belong to the family of large GTPases. In the mouse, the interferon-regulated MX protein is responsible for a specific antiviral state against influenza virus infection. Li and Youssoufian 64 reported that altered MX1 gene expression may play a role in Fanconi anemia. Whether MX1 play a role in pathogenesis of CML or not is not known.
Conclusion
We demonstrate downregulation of L-selectin and ICAM1 in BCR/ABL þ CD34 þ cells, consistent with a role of these genes in altered adhesion and migration properties of CML cells. [9] [10] [11] 49 Furthermore, we show that CCR7 expression is impaired and that this is associated with impaired chemotaxis towards its ligands CCL19 and CCL21. What the role of loss of this ligand/ receptor interaction might be in CML will need to be evaluated further by in vivo homing studies using either human cells in a xenogeneic transplant model, or knockout mouse models.
